Exelixis Inc (EXEL)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+60% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityStrong net margin (35%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is regulatory, centered on the pending FDA decision and pivotal kidney cancer data for zanzalintinib. Given binary regulatory timing and elevated short interest, the probability of the current move continuing over the next few weeks is roughly 40–50%, with meaningful two-way risk around the decision. Informational only — not financial advice.
- Forget clinical cash burns: Why Exelixis is up 38% since JuneYahoo · 2026-11-12
- Exelixis Nears FDA Decision, Key Kidney Cancer Data for ZanzalintinibYahoo · 2026-11-11
- Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeekingAlpha · 2026-11-11
- Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision NearsYahoo · 2026-11-11
- Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptSeekingAlpha · 2026-11-10
Any AI summary is an interpretation of public news, not advice or a price target.